TearLab Corporation reported that it has successfully passed the acceptance review phase with the U.S. Food and Drug Administration (FDA) for the clearance of its TearLab Discovery Platform, the company's next-generation in-vitro diagnostic testing system. The FDA will now progress to the substantive review of the filing. After securing FDA clearance, TearLab intends to pursue a CLIA waiver in an effort to prepare for commercialization in the US market. The Company has multiple additional patents beyond the single Canadian patent in the U.S. protecting the intellectual property around both osmolarity testing and the TearLab Discovery Platform. TearLab continues to prepare for the market introduction of the Discovery Platform, which the company expects in the second half of 2018.